FOXP3 and rheumatoid arthritis: Indeed, these data are strongly at odds with the anticipated outcome of activating p53, which should be an increase of FOXP3+ Tregs as observed in other experimental models of autoimmunity (3, 19, 20) and in PBMC of rheumatoid arthritis (3) and T1D patients (21).